Sofosbuvir + Velpatasvir

Form: Tablet

Strength: Sofosbuvir 400 mg + Velpatasvir 100 mg

Reference Brands: Epclusa® (EU & US)

Category: Hepatitis

Sofosbuvir 400 mg + Velpatasvir 100 mg tablets (Epclusa® generic) are oral antivirals indicated for pan-genotypic Hepatitis C treatment. This once-daily fixed-dose combination is effective across all major HCV genotypes and offers high SVR rates. Manufactured under EU-GMP and USFDA-approved facilities, the product is available for B2B supply, tenders, and contract manufacturing. Regulatory support includes CTD dossiers and bioequivalence studies. Widely accepted across EU, US, LATAM, and MENA markets, Sofosbuvir + Velpatasvir is a key addition to antiviral portfolios targeting global Hepatitis C elimination goals.